HUM241220C210000
- 37.90
- 0.000.00%
Humana Newsroom
Humana Is Maintained at Equal-Weight by Morgan Stanley
Humana Analyst Ratings
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Morgan Stanley Adjusts Price Target on Humana to $301 From $288
Morgan Stanley Maintains Humana(HUM.US) With Hold Rating, Raises Target Price to $301
Morgan Stanley Sticks to Their Hold Rating for Humana (HUM)
Piper Sandler Maintains Humana(HUM.US) With Hold Rating, Cuts Target Price to $270
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
Express News | Humana Inc Shares Hit Lowest Level Since Early Nov, Last Down 3.4% at $264.87
Worst Performing Stocks for Tax Loss Selling – Wolfe
Another Week, Another Index Record | Lkive Stock
Shareholders in Humana (NYSE:HUM) Are in the Red If They Invested a Year Ago
Weekly Buzz: Tech stocks hit high scores on ominous day
Market Mixed on Friday the 13th | Livestock
UnitedHealth Stock Heads for Worst Month Since 2009, CEO Says Healthcare System 'Flawed'
UnitedHealth CEO Talks About Brian Thompson Death for First Time. Calls for Reforms.
Deutsche Bank: If the USA Congress advances PBM reforms, CVS Health (CVS.US), The Cigna Group (CI.US), and others will face severe impacts.
Deutsche Bank believes that if the USA Congress passes legislation requiring Medical Insurance and Pharmaceutical Benefits Management (PBM) companies to divest their Pharmaceutical Business, CVS Health, The Cigna Group, and Humana will be significantly affected.
Thursday Ends in Index Declines | Wall Street Today
'Wanted' Signs Targeting Wall Street and Healthcare Executives Pop Up in New York City -- WSJ
Companies Tighten Security After a Health Care CEO's Killing Leads to a Surge of Threats